Literature DB >> 29034884

Generation of six multiple sclerosis patient-derived induced pluripotent stem cell lines.

L Miquel-Serra1, A Duarri2, Y Muñoz1, B Kuebler1, B Aran2, C Costa3, M Martí1, M Comabella3, S Malhotra3, X Montalban3, A Veiga4, A Raya5.   

Abstract

Multiple sclerosis (MS) is considered a chronic autoimmune disease of the central nervous system that leads to gliosis, demyelination, axonal damage and neuronal death. The MS disease aetiology is unknown, though a polymorphism of the TNFRSF1A gene, rs1800693, is known to confer an increased risk for MS. Using retroviral delivery of reprogramming transgenes, we generated six MS patient-specific iPSC lines with two distinct genotypes, CC or TT, of the polymorphism rs1800693. iPSC lines had normal karyotype, expressed pluripotency genes and differentiated into the three germ layers. These lines offer a good tool to study MS pathomechanisms and for drug testing.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29034884     DOI: 10.1016/j.scr.2017.06.001

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


  4 in total

1.  The Evolution of Stem Cells, Disease Modeling, and Drug Discovery for Neurological Disorders.

Authors:  Cameron Pernia; Brian T D Tobe; Ryan O'Donnell; Evan Y Snyder
Journal:  Stem Cells Dev       Date:  2020-05-06       Impact factor: 3.272

2.  Establishment of Human Induced Pluripotent Stem Cells from Multiple Sclerosis Patients.

Authors:  Onur Can Begentas; Dilara Koc; Erkan Kiris
Journal:  Methods Mol Biol       Date:  2022

Review 3.  Human-Induced Pluripotent Stem Cell-Based Models for Studying Sex-Specific Differences in Neurodegenerative Diseases.

Authors:  Erkan Kiris
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

Review 4.  Open Science Meets Stem Cells: A New Drug Discovery Approach for Neurodegenerative Disorders.

Authors:  Chanshuai Han; Mathilde Chaineau; Carol X-Q Chen; Lenore K Beitel; Thomas M Durcan
Journal:  Front Neurosci       Date:  2018-02-06       Impact factor: 4.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.